Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4863740 | 1.00 | AKR1B1 (0.39) | AKR1B1L3MBTL1HTR2AHTR2CKDM2B | |
| SCHEMBL5751186 | 0.75 | MMP2 (0.42) | AKR1B1L3MBTL1HTR2AHTR2CHTR6 | |
| SCHEMBL7403095 | 0.72 | CHRM2 (0.35) | OPRM1 | |
| SCHEMBL1327443 | 0.67 | TRPA1 (0.44) | HTR2AHTR2CHTR6CYP3A4CYP2D6 | |
| SCHEMBL13990227 | 0.65 | TSHR (0.34) | — | |
| SCHEMBL424172 | 0.64 | PKM (0.71) | L3MBTL1KMT2A | |
| SCHEMBL9965987 | 0.63 | HTR2A (0.58) | HTR2AHTR2C | |
| SCHEMBL1327465 | 0.62 | TRPA1 (0.41) | HTR2AHTR2CHTR6CYP3A4CYP2D6 | |
| SCHEMBL1328129 | 0.62 | KDM4E (0.41) | HTR2AHTR2CHTR6CYP3A4CYP2D6 | |
| SCHEMBL12124759 | 0.60 | HTR2A (0.39) | HTR2AHTR2CHTR6CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2008-12-11 | — | — | US | claimed |
| EP-1507765-A4 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INST BIOLOG RES (IL) | 2006-11-02 | — | — | EP | claimed |
| US-20060052406-A1 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | ISREAL INSTITUTE FOR BIOLOGICAL RESEARCH (US) | 2006-03-09 | — | — | US | claimed |
| EP-1507765-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2005-02-23 | — | — | EP | claimed |
| US-20040044018-A1 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2004-03-04 | — | — | US | claimed |
| WO-2003092580-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2003-11-13 | — | — | WO | claimed |
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2008-12-11 | — | — | US | disclosed |
| EP-1507765-A4 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INST BIOLOG RES (IL) | 2006-11-02 | — | — | EP | disclosed |
| US-7049321-B2 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2006-05-23 | — | — | US | disclosed |
| US-20060052406-A1 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | ISREAL INSTITUTE FOR BIOLOGICAL RESEARCH (US) | 2006-03-09 | — | — | US | disclosed |
| EP-1507765-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2005-02-23 | — | — | EP | disclosed |
| US-20040044018-A1 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2004-03-04 | — | — | US | disclosed |
| WO-2003092580-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | PMP22, PYGB, GAP43 | AKR1B1 500/4885L3MBTL1 4810/4885HTR2A 2069/4885 |
| US-20040044018-A1 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | PMP22, PYGB, GAP43 | AKR1B1 446/4885L3MBTL1 4840/4885HTR2A 1806/4885 |
| US-20060052406-A1 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | PMP22, PYGB, GAP43 | AKR1B1 500/4885L3MBTL1 4810/4885HTR2A 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.